Agios to Present New Clinical Data from its IDH Programs at ASCO
Agios Pharmaceuticals, Inc. (AGIO)
Last agios pharmaceuticals, inc. earnings: 4/30 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.agios.com/investor-overview
Company Research
Source: GlobeNewswire
– Updated Data From Ivosidenib Phase 1 Expansion in IDH1m R/R AML and the First Data from the AG-881 Phase 1 Study in IDHm Glioma to be Highlighted in Oral Presentations – – New Data From Fully Enrolled Ivosidenib Arm of the Phase 1/2 Combination Trial of Enasidenib or Ivosidenib with VIDAZA® in Newly Diagnosed AML to be Featured in Poster Presentation – CAMBRIDGE, Mass., May 16, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that new data from its isocitrate dehydrogenase (IDH) programs will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting being held June 1-5, 2018 in Chicago. In total, five abstracts led by Agios describing new data from the company's IDH programs have been accepted for presentation at ASCO, as well as one abstract led by Celgene Corporation. IDHIFA® (enasidenib) is being commercialized in collaboration with
Show less
Read more
Impact Snapshot
Event Time:
AGIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AGIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AGIO alerts
High impacting Agios Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AGIO
News
- Wall Street Analysts See a 26.01% Upside in Agios Pharmaceuticals (AGIO): Can the Stock Really Move This High? [Yahoo! Finance]Yahoo! Finance
- Agios to Present at the BofA Securities 2024 Health Care Conference on May 16, 2024GlobeNewswire
- Earnings Beat: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts [Yahoo! Finance]Yahoo! Finance
- Agios (AGIO) Q1 Earnings Surpass, Sales Miss Estimates [Yahoo! Finance]Yahoo! Finance
- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $29.00 to $33.00. They now have a "neutral" rating on the stock.MarketBeat
AGIO
Earnings
- 5/2/24 - Beat
AGIO
Sec Filings
- 5/2/24 - Form 10-Q
- 5/2/24 - Form 8-K
- 4/26/24 - Form ARS
- AGIO's page on the SEC website